Resistance of Pseudomonas aeruginosa to ciprofloxacin and levofloxacin: 1998-2002;Resistenza di Pseudomonas aeruginosa a ciprofloxacina e levofloxacina: 1998-2002

Infezioni in Medicina

Volumn 11, Issue 4, 2003, Pages 196-200

  De Vecchi, Elena ^a   Drago, Lorenzo ^a   Nicola, Lucia ^a   Colombo, Alberto ^a   Guerra, Anna ^a   Tocalli, Loredana ^a   Medaglia, Massimo ^a   Gismondo, Maria Rita ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Bacterial resistance; Ciprofloxacin; Levofloxacin; Pseudomonas aeruginosa

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BLOOD; EAR; ITALY; NONHUMAN; PSEUDOMONAS AERUGINOSA; SPUTUM; TRACHEOBRONCHIAL TOILET; URINE;

BODY FLUIDS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; HUMANS; OFLOXACIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES;

EID: 0742305755     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Hancock R.E.W. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin. Infect. Dis. 27 (Suppl. 1), S93-S99, 1998.
2. Bonfiglio G., Laksai Y., Franchino L., Amicosante G., Nicoletti G. Mechanisms of b-lactam resistance amongst Pseudomonas aeruginosa isolated in an Italian survey. J. Antimicrob. Chemother. 42, 697-702, 1998.
3. Vahaboglu H., Coskunkan F., Tansel O., et al. Clinical importance of extended spectrum beta-lactamase (PER-1 type)-producing Acinetobacter spp. and Pseudomonas aeruginosa strains. J. Med. Microbiol. 50, 642-645, 2001.
4. Waterer G.W., Wunderink R.G. Increasing threat of Gram-negative bacteria. Crit. Care Med. 29 (Suppl.4), N75-N81, 2001.
5. Chastre J., Trouillet J.L. Problem pathogens (Pseudomonas aeruginosa and Acinetobacter). Sem. Resp. Infect. 15, 287-298, 2000.
6. Jones R.N., Kirby J.T., Beach M.L., Biedenbach D.J., Pfaller M.A. Geographic variations in activity of broad spectrum β-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn. Microbiol. Infect. Dis. 43, 239-243, 2002.
7. Gales A.C., Jones R.N., Turnidge J., Rennie R., Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY antimicrobial surveillance program, 1997-1999. Clin. Infect. Dis. 32, (Suppl 2), S146-S155, 2001.
8. Jones R.N., Pfaller M.A. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program. Clin. Infect. Dis. 31 (Suppl 2), S16-23, 2000.
9. Hurst M., Lamb H.M., Scott L.J., Figgitt D.P. Levofloxacin: an updated review of its use in the treatment of bacterial infections. Drugs 62, 2127-2167, 2002.
10. Schaeffer A.J. The expanding role of fluoroquinolones. Am. J. Med. 113 (Suppl 1A), 45S-54S, 2002
11. Bonfiglio G., Is levofloxacin as active as ciprofloxacin against P. aeruginosa? Chemotherapy 47, 239-242, 2001.
12. Segatore B., Setacci D., Perilli M., et al. Italian survey on comparative levofloxacin susceptibility in 334 clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43, 428-431, 1999.
13. Karlowsky J.A., Kelly L.J., Thornsberry C., et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Int. J. Antimicrob. Agents. 19, 21-31, 2002.
14. Richard P., Delangle M.H., Raffi F., Espaze E., Richet H. Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora. Clin. Infect. Dis. 32, 162-166, 2001.
15. Kolar M., Latal T., Hajek V. Development of bacterial resistance to the third generation cephalosporins and their clinical use. J. Chemother. 11, 260-265, 1999.
16. Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new "respiratory quinolones". J. Antimicrob. Chemother. 43 (Suppl B), 1-11, 1999.
17. Bauerfeind A. Comparison of the antibacterial activity of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin clinafloxacin levofloxacin and ciprofloxacin. J. Antimicrob. Chemother. 40, 639-651, 1997.
18. Aminimanizani A., Beringer P., Jellife R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin. Pharmacokin. 40, 169-187, 2001.
19. Gesu G.P., Marchetti F., Piccoli L., Cavallero A. Levofloxacin and ciprofloxacin in vitro activities against 4,003 clinical bacterial isolates collected in 24 italian laboratories. Antimicrob. Agents Chemother. 47, 816-819, 2003.
20. Shen L.L. Molecular mechanisms of DNA gyrase inhibition by quinolone antibacterials. Adv. Pharmacol. 29A, 285-304, 1994.
21. Spanu T., Ardito F., Velardi G., Siddu A., Fadda G. Attività in vitro di b-lattamici, aminoglicosidi e ciprofloxacina nei confronti di 515 ceppi di Pseudomonas aeruginosa isolati dalle secrezioni respiratorie di pazienti ospedalizzati. Microbiologia Medica 14 (Suppl.1), S1-S11, 1999.